Switch theme
Sign up to access all valuation multiples
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by Asia and Latin America.
1968
5.5K+
LTM Revenue $1.5B
LTM EBITDA $306M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Virbac has a last 12-month revenue of $1.5B and a last 12-month EBITDA of $306M.
In the most recent fiscal year, Virbac achieved revenue of $1.3B and an EBITDA of $248M.
Virbac expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Virbac valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | XXX | XXX | XXX |
| Gross Profit | $761M | $849M | XXX | XXX | XXX |
| Gross Margin | 58% | 63% | XXX | XXX | XXX |
| EBITDA | $246M | $248M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 18% | XXX | XXX | XXX |
| Net Profit | $122M | $131M | XXX | XXX | XXX |
| Net Margin | 9% | 10% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Virbac's stock price is EUR 296 (or $318).
Virbac has current market cap of EUR 2.5B (or $2.7B), and EV of EUR 2.6B (or $2.8B).
See Virbac trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.7B | XXX | XXX | XXX | XXX | $19.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Virbac has market cap of $2.7B and EV of $2.8B.
Virbac's trades at 1.9x LTM EV/Revenue multiple, and 9.3x LTM EBITDA.
Analysts estimate Virbac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Virbac and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | XXX | XXX |
| P/E | 20.5x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | 44.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVirbac's NTM/LTM revenue growth is 6%
Virbac's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Virbac's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Virbac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Virbac and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 24% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 50% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Mad Paws | XXX | XXX | XXX | XXX | XXX | XXX |
| i-Tail | XXX | XXX | XXX | XXX | XXX | XXX |
| Central Garden & Pet | XXX | XXX | XXX | XXX | XXX | XXX |
| Dogness | XXX | XXX | XXX | XXX | XXX | XXX |
| Freshpet | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Virbac acquired XXX companies to date.
Last acquisition by Virbac was XXXXXXXX, XXXXX XXXXX XXXXXX . Virbac acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Virbac founded? | Virbac was founded in 1968. |
| Where is Virbac headquartered? | Virbac is headquartered in France. |
| How many employees does Virbac have? | As of today, Virbac has 5.5K+ employees. |
| Is Virbac publicy listed? | Yes, Virbac is a public company listed on PAR. |
| What is the stock symbol of Virbac? | Virbac trades under VIRP ticker. |
| When did Virbac go public? | Virbac went public in 1989. |
| Who are competitors of Virbac? | Similar companies to Virbac include e.g. Mad Paws, i-Tail, Central Garden & Pet, Dogness. |
| What is the current market cap of Virbac? | Virbac's current market cap is $2.7B |
| What is the current revenue of Virbac? | Virbac's last 12-month revenue is $1.5B. |
| What is the current EBITDA of Virbac? | Virbac's last 12-month EBITDA is $306M. |
| What is the current EV/Revenue multiple of Virbac? | Current revenue multiple of Virbac is 1.9x. |
| What is the current EV/EBITDA multiple of Virbac? | Current EBITDA multiple of Virbac is 9.3x. |
| What is the current revenue growth of Virbac? | Virbac revenue growth between 2023 and 2024 was 3%. |
| Is Virbac profitable? | Yes, Virbac is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
